The global digital twins market is projected to grow at a CAGR of 30% till 2035, claims Roots AnalysisFor additional details, please visit https://www.rootsanalysis.com/....reports/digital-twin or email sales@rootsanalysis.com

DRIVEN BY THE GROWING DEMAND FOR MEDICAL DEVICES, NOVEL COATINGS PROVIDING UNIQUE FEATURES ARE BEING INTRODUCED IN THE MARKETFor additional details, please visit https://www.rootsanalysis.com/....reports/medical-devi or email sales@rootsanalysis.com

The novel antibody therapies market for advanced stage drugs is anticipated to grow at a CAGR of 36% by 2035, claims Roots Analysis
Roots Analysis has announced the addition of “Novel Antibody Therapies Market, 2022-2035” report to its list of offerings.

Antibodies are the key components of immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinct malignantly transformed cells from regular cells.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/novel-antibo

Key Market Insights

Presently, 140+ novel antibody therapies have been marketed / are being evaluated across different phases of development for the treatment of various disease indications
Till date, five novel antibody therapies have been marketed and close to 80% of the pipeline candidates are under clinical evaluation. It is worth mentioning that most of the drug candidates are immunotoxins (34%), followed by immunocytokines (32.5%). Majority of these therapies are under clinical trials for the treatment of lymphoma (22) followed by solid tumors (19) and leukemia (18).

Around 60 industry and non-industry players are engaged in the development of novel antibody therapies, globally
North America has emerged as the hub, featuring the presence of approximately 60% developers. The market is currently dominated by the presence of small players (27%). Interestingly, 16% of the players are big pharma companies engaged in the development of such therapeutics for multiple target indications.

More than 550 clinical trials have been registered for the evaluation of novel antibody therapies, worldwide
The clinical research activity, in terms of number of trials registered, is reported to have increased at a steady CAGR of 8%, during the period 2016-2021. Of the total number of trials registered, close to 60% have already been completed, while 25% of the studies are actively recruiting participants.

Close to 600 articles related to novel antibody therapies, have been published in reputed scientific journals, since 2017
More than 95% of the articles focused on novel antibody therapies were published post-2019. Popular journals that have published multiple articles include Cancer, Frontiers in Immunology, International Journal of Molecular Sciences and Scientific Reports.

Over 4,600 patents have been filed / granted related to novel antibody therapies, since 2017
More than 1,150 patents were filed / granted in 2021. Further, around 56% of the patents were filed in North America. It is worth highlighting that majority of the patents were granted / filed by prominent industry / non-Industry players, such as Novartis, Hoffmann la Roche, Immatics Biotechnologies
and Pfizer.

Partnership activity in this field has increased at a CAGR of over 55%, since 2018
Around 50% of the reported deals were established post-2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the agreements were supply agreements (19%), followed by product development and commercialization agreements (15%).

North America is anticipated to capture larger share of the phase III novel antibody therapies market by 2035
Around 40% of the market revenues are likely to be generated from the sales of drug candidates being evaluated in phase III for bladder cancer. Further, therapies designed for intravenous route of administration are expected to occupy close to 70% of the overall market.

For additional details, please visit https://www.rootsanalysis.com/....reports/novel-antibo or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

The needlestick safety injection devices market is anticipated to grow at a commendable pace by 2035, claims Roots Analysis
An exponential increase in the annual cost burden due to needlestick injuries, has fueled a corresponding rise in demand for safe and highly advanced safety devices to be developed by the stakeholders engaged in the healthcare industry to generate a stringent regulation for the prevention of needle-stick injuries.
Roots Analysis has announced the addition of “Needlestick Safety Injection Devices Market, 2022-2035” report to its list of offerings.

Given the inherent benefits of needlestick safety injection devices, number of developers have launched their proprietary devices for minimizing the risk of needlestick injuries. Moreover, stringent regulatory requirements have further prompted the stakeholders to improve product design and integrate better safety measures in their products, including needle shielding.


Key Market Insights

Currently, around 120 needlestick safety injection devices are available in the market
More than 35% of these injection devices are needles having the ability to retract or shield, followed by syringes (30%). It is worth noting that more than 90% of the needlestick safety injection devices are non-reusable (intended for single use) thereby reducing the chances of blood borne pathogen infections.

Over 50 companies claim to develop needlestick safety injection devices, worldwide
Presently, the market is dominated by very small companies (33%) and small companies (25%). It is worth noting that majority (40%) of the firms engaged in this domain are based in Europe, followed by North America (39%).

Partnership activity within this field has grown significantly between 2020 and 2022
Maximum number of partnerships (31%) were established in 2020 indicating a recent rise in the interest of developers engaged in the development of needlestick safety injection devices. It is worth highlighting that majority of the deals were acquisitions.

Over USD 260 million has been invested by both private and public investors, since 2016
Companies involved in the development of needlestick safety injection devices have raised around USD 70 million through venture funding, which represents 25% of the total capital raised in the given time period. Overall, around 20 investors have actively financed various projects / initiatives in this domain.

Close to 20 global events were organized in the past couple of years in this industry
Majority of the events related to needlestick safety injection device were organized in North America (22%). It is worth highlighting that the main agenda of these events was to discuss role of needlestick safety injection devices to prevent the needlestick injuries.

More than 140 patents have been filed / granted related to needlestick safety injection devices, since 2018
Of these, over 60 patents were filed / granted in 2022 (till April). Industry players that have filed maximum number of patents related to needlestick safety injection devices include (in decreasing order of number of patents filed) BD, West Pharmaceutical Services, B. Braun, Retractable Technologies and Safety Syringes.

North America and Europe are anticipated to capture more than 75% of the market by 2035
Growth in this domain is anticipated to be primarily driven by the rising cases of needlestick injuries amongst the healthcare workers. The Asia-Pacific needlestick safety injection devices market currently accounts for more than 20% of the global market.


To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/....reports/needlestick-


Key Questions Answered
 Who are the leading needlestick safety injection devices developers?
 Which are the popular types of safety injection devices available in this market?
 What are the key challenges faced by stakeholders engaged in the development of needlestick safety injection devices?
 What types of partnership models are commonly being adopted by stakeholders in this industry?
 How has the intellectual property landscape of needlestick safety injection devices developers evolved over the years?
 Which factors are likely to influence the evolution of this market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The research also includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), details on product portfolio, recent developments, and an informed future outlook.
 B. Braun
 BD
 Gerresheimer
 HTL-STREFA
 Nipro Europe Group Companies
 SOL-MILLENNIUM Medical Group

For additional details, please visit https://www.rootsanalysis.com/....reports/needlestick- or email sales@rootsanalysis.com


You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

The mini bioreactors and microbioreactors market is anticipated to grow at an annualized rate of 8% till 2035, claims Roots Analysis

Given the need for accelerated bioprocessing operations, low-volume bioreactors have emerged as a relatively economic solution for parallelized cell cultivations and applications ranging
Roots Analysis has announced the addition of “Mini Bioreactors and Micro Bioreactors Market, 2022-2035” report to its list of offerings.

Mini bioreactors and microbioreactors enable faster experimental throughput at relatively lower costs and allow bioprocessing of samples, thereby reducing the downtime and increasing the number of batches produced in a given period of time. Moreover, stakeholders in this domain are also focused on incorporating a variety of features for monitoring of different control parameters, such as CO2 levels, dissolved oxygen, pH and temperature ranges, in order to analyze and determine essential conditions of the culture environment and optimize the overall performance.

Key Market Insights

Currently, over 60 mini bioreactors and micro bioreactors are available in the market
Majority (55%) of these equipment are single-use bioreactors, followed by reusable bioreactors, which constitute around 24% of the total number of mini bioreactors and micro bioreactors available in the market.

More than 25 companies are engaged in the development of mini bioreactors and micro bioreactors
The current market landscape features the presence of both well-established players and new entrants; however, more than 70% of the players are small and mid-sized companies. Further, majority (more than 57%) of the developers are headquartered in Europe, followed by North America (25%) and Asia-Pacific (18%).

More than 250 patents related to mini bioreactors and micro bioreactors, were filed since 2016
Of these, over 70% were patent applications, while around 28% were granted patents. Of the total granted patents, close to 42% were filed in North America, followed by WIPO (36%), Europe (14%) and Asia-Pacific (8%).

North America is anticipated to capture over 35% of the global market share in 2035
Mini bioreactors and micro bioreactors developed for batch / fed-batch operations are likely to capture the highest market share (90%). Further, in terms of revenues generated from the product sales, North America is likely to capture the maximum share in the global market, followed by Europe (31%) and Asia Pacific (22%).

To request a sample copy / brochure of this report, please visit link https://www.rootsanalysis.com/....reports/mini-bioreac

Key Questions Answered

 Who are the leading manufacturers engaged in the development of mini bioreactors and micro bioreactors?
 What are the key application areas where mini bioreactors and micro bioreactors are currently being used?
 What are the challenges currently faced by stakeholders in mini bioreactors and micro bioreactors market?
 What are the key factors that are likely to influence the evolution of mini bioreactors and micro bioreactors market?
 How is the current and future opportunity, related to mini bioreactors and micro bioreactors, likely to be distributed across key market segments?
 What are the anticipated future trends related to minibioreactors and microbioreactors market?


The financial opportunity within the minibioreactors and microbioreactors market has been analyzed across the following segments:

• Type of Cell Culture
o Mammalian Culture
o Microbial Culture
o Viral Culture
o Insect Culture
o Other Cell Culture

• Mode of Operation
o Batch / Fed-Batch reactors
o Continuous reactors

• End User
o Biopharmaceutical / Pharmaceutical Industries
o Academic / Research Institutes

• Geographical Regions
o North America
o Europe
o Asia Pacific
o Rest of the World

The research includes detailed profiles of key players (listed below) engaged in the development of mini bioreactors and micro bioreactors; each profile features an overview of company, details on, mini bioreactors and micro bioreactors product portfolio, recent developments, and an informed future outlook.
 BIONET
 Biosan
 Cytiva
 Distek
 Eppendorf
 Merck Millipore
 Pall Corporation
 Sartorius

For additional details, please visit link https://www.rootsanalysis.com/....reports/mini-bioreac or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com